Skip to main content
Caplight Logo









RongCan Biotech

RongCan Biotech

Private
ShanghaiHealthcare & Life Scienceshttp://rc-rna.com/

Last Round

Series A

Extension

Sep 28, 2025

Total Funding Raised

$14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

RongCan Biotech is a biotechnology company that develops nucleic acid-based therapeutics, including mRNA vaccines and LNP-based delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

mRNA therapeuticsLNPlipid nanoparticlerna drug developmentnucleic acid medicinerna platformsiRNA therapeuticsmRNA vaccinedrug discovery platformgene therapyCMCchemistry, manufacturing, and controlsbiotech CDMOdrug delivery technologybiopharma partner

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RongCan Biotech Comparables

Compare RongCan Biotech with similar companies based on industry and business-model similarity.

RongCan Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shenzhen MagicRNA Biotechnology Co., Ltd.
89%
Starna Therapeutics
87%
Immorna Biotherapeutics
86%

RongCan Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 28, 2025
Series ADec 6, 2023
Early FundingApr 6, 2023
Early FundingNov 21, 2022
AngelJun 15, 2021

RongCan Biotech Investors

Notable investors and investment history

RongCan Biotech investors
InvestorRounds
Lilly Asia VenturesAngel
Guangzhou Yuexiu Industrial Investment Fund ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 28, 2025

    Completed a Series A Extension round.

  • Dec 6, 2023

    $14M round led by Guangzhou Yuexiu Industrial Investment Fund Management

RongCan Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RongCan Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RongCan Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2020
Last FundingSep 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?